Vir Biotechnology, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Vir Biotechnology, Inc.
- Company name
- Vir Biotechnology, Inc.
- Organisation type
- Industry
- Registered legal name
- Vir Biotechnology, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- Website
- https://www.vir.bio/
- SEC filer number (CIK)
- 0001706431
- Wikidata ID
- Q77083018
Related records
Trials (35)
- A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
- A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
- A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
- A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
- ACTIV-3: Therapeutics for Inpatients With COVID-19
- Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
- Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
- Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
- Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
- Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19